Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

myelodysplastic syndrome with excess blasts-1 - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

myelodysplastic syndrome with excess blasts-1

MONDO:0015040

Also known as:MDS-EB-1RAEB-1RAEB-I

Find Clinical TrialsTrials

Overview

A myelodysplastic syndrome defined by 5-9% blasts in the bone marrow, and <5% blasts in the blood. Approximately 25% of cases progress to an acute leukemia. (WHO)

Clinical Trials4 registered · 1 recruiting

ResearchLimited published research (4 articles)

Diagnosis

Biomarker and diagnostic research for myelodysplastic syndrome with excess blasts-1 has been reported in the published literature.

Prognosis

Estimated prevalence: Unknown (Unknown prevalence).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

4 clinical trials registered, 1 recruiting. Interventions under study include drug therapy, other interventions, procedural interventions, and biologic therapy. Pipeline includes 3 PHASE2, 1 PHASE1. Research is primarily sponsored by academic and government institutions.

4 publications have been identified in PubMed for myelodysplastic syndrome with excess blasts-1. Research spans Diagnostic / Biomarker (25%), Review / Meta-Analysis (25%), and Case Report / Case Series (25%).

Recent Publications

Koorse Germans S (2026). [PMID: 41720165](https://pubmed.ncbi.nlm.nih.gov/41720165/). *Human pathology*. [Review / Meta-Analysis]
Sicre de Fontbrune F (2026). [PMID: 39159950](https://pubmed.ncbi.nlm.nih.gov/39159950/). *British journal of haematology*. [Clinical Trial Publication]
Eifer M (2025). [PMID: 39978813](https://pubmed.ncbi.nlm.nih.gov/39978813/). *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*. [Case Report / Case Series]
Moore ME (2024). [PMID: 38964162](https://pubmed.ncbi.nlm.nih.gov/38964162/). *Cancer genetics*. [Diagnostic / Biomarker]

Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 3:09 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Patient Support

Financial & Access Support (External Programs)

View all programs →

Myelodysplastic Syndrome Program

Premium/CopayClosedOperated by Good Days

Visit official site

Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.

Are you a patient organization for this condition?

Claim this page and your organization will be listed here for patients and families to find.

Be recognized as the official organization
Get notified of new trials, FDA decisions, and research
Appear in the disease page directory
Embed this content on your website — free

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:100019

GARD

Genetic and Rare Diseases Info Center

GARD:19737

Questions for Your Care Team

→Are any of the 4 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

myelodysplastic syndrome with excess blasts-1

Overview

Diagnosis

Prognosis

Research Landscape

Recent Publications

Patient Support

Financial & Access Support (External Programs)

Are you a patient organization for this condition?

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team